Global scientists develop South-East Asian population genome dataset
SOUTH-EAST ASIA (Xinhua): A group of international researchers has constructed a comprehensive Southeast Asian population genome variation dataset, according to the Kunming Institute of Zoology (KIZ) under the Chinese Academy of Sciences.
Mainland Southeast Asia (MSEA) has rich ethnic and cultural diversity with a population of nearly 300 million. However, people from MSEA are underrepresented in the current human genomic databases.
The researchers from countries including China, Thailand and Cambodia spent more than 10 years venturing deep into the rainforests of South-East Asian countries and collecting samples from South-East Asian populations covering five major language families in six countries.
They successfully completed whole-genome deep sequencing of 3,023 samples.
The international researchers have, for the first time, comprehensively mapped the genetic variation and genomic structure of South-East Asian populations.
The study is now also revealing how the genomic landscape of the region has been shaped by the combined effects of ancient population differentiation, admixture, adaptation, changes in population size and gene flow from archaic humans, according to their research article published in the journal Nature.
Additionally, the study has revealed the genetic mechanisms underlying phenotypic traits related to adaptation to tropical rainforests, such as skin color, body height and malaria resistance.
This provides important evidence for understanding how natural selection has shaped modern human phenotypic diversity.
The study has also detected multiple traces of Denisovan gene flow in South-East Asian indigenous populations, suggesting that this archaic human group may have been widely distributed across the vast region stretching from Siberia to South-East Asia, the KIZ said.
This finding redefines the geographical boundaries of human prehistoric evolution.
Phase II of the genome dataset has been initiated, according to the KIZ, which is dedicated to building a high-resolution genomic map covering the entire South-East Asian region. - Xinhua
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
COVID-19 virus protein triggers immune attack on healthy cells: study
JERUSALEM, June 10 (Xinhua) -- Israeli researchers have discovered that a protein from the SARS-CoV-2 virus, responsible for COVID-19, can cause the immune system to attack healthy cells mistakenly, the Hebrew University of Jerusalem said in a statement on Tuesday. The study, published in Cell Reports, sheds light on how severe COVID-19 complications may occur and suggests new ways to prevent immune-driven damage from the virus. The researchers found that the virus's nucleocapsid protein (NP), which normally helps package the virus's genetic material inside infected cells, can spread to nearby uninfected epithelial cells. Once on the surface of these healthy cells, NP would be mistakenly identified by the immune system as a threat. The immune system then deploys anti-NP antibodies, which mark these uninfected cells for destruction. The process triggers the classical complement pathway, a part of the immune response that leads to inflammation and tissue damage, contributing to severe COVID-19 symptoms and possibly long COVID. Using lab-grown cells, advanced imaging, and samples from COVID-19 patients, the researchers found that NP binds to a type of molecule on cell surfaces. The binding causes the protein to cluster on healthy cells, further confusing the immune system. The study also found that the drug enoxaparin, a common blood thinner and heparin analog, blocks NP from sticking to healthy cells. In both lab tests and patient samples, enoxaparin helped prevent immune attacks by occupying the binding sites that NP uses. According to the researchers, the discovery may offer new hope for reducing immune-related complications in COVID-19 and potentially other viral infections.
New Straits Times
2 days ago
- New Straits Times
China joins global scientists in exploring hadal zone
HAIKOU: A pioneering international initiative for hadal zone exploration, led by Chinese scientists, has received official approval from the United Nations Decade of Ocean Science for Sustainable Development (2021-2030), Xinhua reported. The Global Hadal Exploration Programme (GHEP), spearheaded by the Institute of Deep-sea Science and Engineering (IDSSE) under the Chinese Academy of Sciences (CAS), aims to transform fragmented hadal research into a coordinated global mission to explore, understand and protect the planet's most inaccessible marine ecosystems. The hadal zone comprises primarily of ocean trenches, particularly from a depth of 6,000 metres to the bottom of the ocean up to about 11,000 metres. The hadal environment is characterised by extreme depths and pressures, darkness, low temperatures, frequent earthquakes, and peculiar living forms. For a long time, the hadal trenches have been among the most under-explored and mysterious areas on earth due to technological limitations. China has been a key driver of deep-sea exploration over the past decade through sustained sci-tech advancements. In 2014, the CAS launched the Hadal Science and Technology Programme, followed by a historic dive to the Mariana Trench's 10,000-metre depths in 2016. By 2022, the CAS initiated the Global Trench Dive and Exploration Programme, leveraging its cutting-edge manned submersible Fendouzhe (Striver) and the Tansuo research vessels. "Venturing deeper is about understanding our ocean so we can coexist with it," said Du Mengran, a lead researcher at IDSSE. "Global cooperation in these 'untouched zones' will redefine the boundaries of marine science and provide critical knowledge for deep-sea conservation and sustainable use," she said. To date, Chinese scientists have collaborated with 145 researchers from 10 countries, exploring nine hadal trenches worldwide, including the Mariana, the Kermadec and Puysegur trenches. Starting from this year, GHEP will unify international research on extreme environments, life evolution, and geological processes in the hadal zone. The programme will establish international research hubs, organise joint deep-diving expeditions, and host regular symposia while offering training and open access to samples, data, and facilities – particularly for young scientists, Du added. GHEP brings together research institutions from New Zealand, Denmark, Germany, Chile, France, Indonesia, Brazil, Russia, India, the Cook Islands, Papua New Guinea, Singapore, Portugal and other countries. – Bernama
Borneo Post
3 days ago
- Borneo Post
China's homegrown 9-valent HPV vaccine expected to boost immunisation coverage
A girl receives a human papillomavirus (HPV) vaccine at the provincial Maternity and Child Healthcare Hospital in Wuhan, central China's Hubei Province, May 18, 2020. – Xinhua photo BEIJING (June 8): China's drug regulator has approved the country's first domestically developed 9-valent human papillomavirus (HPV) vaccine, ending over a decade of foreign dominance in the market. The vaccine, Cecolin 9, has been included on a list of approved medical products that was made public by the National Medical Products Administration on Wednesday. 'The approval of Cecolin 9 not only offers more vaccination options for eligible women in China, but is also expected to improve vaccine accessibility and coverage, reducing the risk of cervical cancer further,' said Zhang Jun, dean of the School of Public Health at Xiamen University and a leading member of the vaccine development team. HPV vaccines are commonly used to prevent cervical cancer in women, as well as genital cancers and warts in both men and women. Cecolin 9, which targets nine HPV strains, was developed by Xiamen University, the Xiang An Biomedicine Laboratory and Xiamen Innovax Biotech Co., Ltd, marking a breakthrough in China's ability to produce high-valency HPV vaccines independently. China is now the second country – after the United States – capable of supplying 9-valent HPV vaccines. Compared to bivalent HPV vaccines, which are effective against two high-risk genotypes (HPV 16 and 18), 9-valent HPV vaccines protect against an additional five high-risk genotypes (HPV 31, 33, 45, 52 and 58) and two low-risk genotypes (HPV 6 and 11), and provide better protection against cervical cancer. Over 18 years of research, scientists overcame major technical challenges in producing virus-like particles (VLPs) from multiple HPV types using an E. coli platform, and completed crucial clinical trial validation processes. Five related clinical trials have been conducted across China since 2019, and the vaccine has demonstrated a favorable safety profile and a strong immune response, comparable to those of similar international products. Statistics show that globally, approximately 700,000 cancer cases each year are associated with HPV, including an estimated 530,000 cases of cervical cancer. Vaccination is up to 94 percent effective in preventing HPV infection. In 2020, the World Health Organisation (WHO) launched a global strategy to accelerate the elimination of cervical cancer, aiming for 90 percent of girls to be fully vaccinated against HPV by the age of 15 by 2030. In alignment with the WHO strategy, China's National Health Commission launched a cervical cancer elimination action plan for the 2022-2030 period, urging the expansion of HPV vaccination coverage nationwide. 9-valent human papillomavirus China hpv vaccine
